DexCom initiated with an Outperform at Wolfe Research

Wolfe Research analyst Mike Polark initiated coverage of DexCom with an Outperform rating and $121 price target. The company’s "generational investment" in Malaysia winding down, likely freeing cash flow in 2024 and beyond and bringing global production capacity to 200M sensors, which could support at least a tripling of the its user base, the analyst tells investors in a research note.